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Abstract: Domain III of the dengue virus envelope protein (EDIII, aa295-395) has an 
immunoglobulin fold and is the proposed receptor-binding domain of the virus. Previous 
studies have shown that monoclonal antibodies against EDIII can be neutralizing and have 
therapeutic potential. Here, cloned Fab-phage libraries of human and mouse origin were 
screened for DENV specific antibodies. Firstly, bacterially expressed EDIII or whole virus 
particles were used as bait in biopanning against a large naïve human Fab-phage library  
(>10 billion independent clones). Multiple panning strategies were employed, and in excess 
of 1000 clones were screened, but all of the antibodies identified bound the envelope in 
regions outside EDIII suggesting EDIII antibodies are virtually absent from the naïve 
human repertoire. Next, a chimeric Fab-phage library was constructed from a panel of 
EDIII specific mouse hybridomas by pooling the VH and VL chain sequences from the 
hybridomas and cloning these into the pComb3X phagemid vector with human CH and  
CL encoding sequences. Biopanning against EDIII identified a unique antibody (C9) that 
cross-reacts with EDIII from DENV1-3 and, in the IgG format, binds and neutralizes DENV2 
in cell-based assays. Sequence analysis and saturation mutagenesis of complementary 
determining regions (CDR) in the C9 light chain suggest an antigen recognition model in 
which the LCDR3 is a key determinant of EDIII specificity, while modifications in LCDR1 
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and LCDR2 affect DENV serotype cross-reactivity. Overall, this study supports the current 
prevailing opinion that neutralizing anti-EDIII monoclonal antibodies can be readily 
generated in murine systems, but in humans the anti-DENV immune response is directed 
away from domain III. 
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1. Introduction 
Dengue virus (DENV) is a mosquito-borne Flavivirus responsible for at least 100 million 
symptomatic infections each year. There are four circulating serotypes of dengue (DENV1-4) that 
show approximately 70% sequence homology [1]. A primary infection provides effective long-term 
protection against re-infection with the same serotype, but can increase disease severity upon infection 
with a different serotype. This process, termed antibody dependent enhancement (ADE), is thought to 
be facilitated by poorly neutralizing cross-reactive antibodies generated in the primary infection that 
promote virus entry via Fcγ receptor bearing cells such as monocytes [2,3]. 
The envelope (E) protein of DENV is the major target of the humoral response following a DENV 
infection, although B-cell responses towards the structural protein, precursor membrane (prM), and 
non-structural protein 1 (NS1) have also been reported [4–6]. Structural analysis of the flavivirus E 
protein has identified three beta barrel domains: EDI, EDII and EDIII, with the native protein forming 
a head-to-tail homodimer [7]. Domain II has a long, finger-like structure and harbors the fusion peptide, 
while EDIII has an immunoglobulin-like fold and is the proposed receptor-binding domain of the virus 
[8–10]. EDI connects domain II and III to form the hinge region and plays a pivotal role in the 
structural rearrangement of E from a homodimer to a trimer, which occurs on exposure to acidic 
conditions in the trans-Golgi secretory pathway. The reorganized E trimer exposes the hydrophobic 
fusion loop in EDII to mediate cellular fusion [11]. 
Murine monoclonal antibodies (mAbs) that bind all three domains of E have been identified, but  
the most potent neutralizing murine mAbs tend to bind to EDIII [12–15]. Epitope mapping studies 
have shown that murine mAbs with the strongest neutralizing activity are generally serotype specific 
and bind the lateral ridge region of EDIII (BC, DE and FG loops, Figure 1) where sequence diversity 
between serotypes is high, while cross-reactive murine mAbs that bind conserved lysines on the A 
strand (Figure 1) are generally weaker neutralizers [12,15]. Until very recently the immune repertoire 
generated in response to DENV infections in humans was poorly characterized, but an emerging body 
of data suggests that the strong immune response to EDIII exhibited by mice may not be mirrored  
in humans. Serological studies have found the relative proportion of EDI/EDII reactive antibodies 
generated following DENV infections in humans is significantly higher than EDIII reactive   
antibodies [16,17], and in two separate analyses the anti-EDIII response in human sera has been shown 
to contribute little or nothing to overall DENV neutralization [16,18]. However, human EDIII-specific 
mAbs generated by B-cell immortalization were shown to neutralize DENV in a lethal mouse  
model [19], suggesting that EDIII specific antibodies, though individually neutralizing, are of low 
abundance in the human repertoire. Int. J. Mol. Sci. 2012, 13                 
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In this study cloned antibody libraries of human and mouse origin have been utilized, as sources of 
DENV specific antibodies, in a bid to further understand the anti EDIII immune response. Initially a 
large (>10 billion independent clones), naïve Fab (fragment antibody binding) phage library derived 
from 14 non-immune human donors was panned using EDIII or whole virus particles as bait, and 
several DENV specific Fab were isolated and evaluated for their binding specificities. In an alternative 
approach, a Fab-phage library was constructed from a panel of EDIII specific mouse hybridomas. The 
hybridomas had been obtained by immunizing BALB/c mice with EDIII from DENV2, and included 
9F12, which has been shown to neutralize DENV in a prior study [20]. Using phage display to clone 
antibodies from hybridomas enables contaminating, non-functional, heavy and light chain (VH and VL) 
mRNA sequences often present in hybridomas to be eliminated during biopanning [21]. Biopanning 
against EDIII identified unique clones with specificity for DENV, the most promising of which  
cross-reacts with EDIII from DENV1-3. 
Figure 1. (A) Structure of dengue virus 2 (DENV2) E protein domain III (aa295-395) in 
ribbon representation (PDB 1OAN). Residues comprising the 9F12 epitope are marked in 
orange including conserved lysines in the A-strand (K305, K307, K310) and G330 on the BC 
loop. Residues recognized by 3H5 in the FG loop are marked in cyan; (B) size exclusion 
chromatography (SEC) profile for refolded DENV1 EDIII protein using a S75 10/300 
column. The major elution peak corresponds to monomeric EDIII (marked by arrow); (C) 
Far-UV circular dichroism spectra of DENV3 EDIII. 
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2. Results 
2.1. Biopanning the Naïve Human Fab Library (HX02) with EDIII 
EDIII proteins from all four DENV serotypes were purified and refolded with yields ranging  
2–10 mg/L of culture. Correct folding of the proteins was confirmed by size exclusion chromatography 
(SEC), which showed each of the EDIII proteins to be monomeric, and circular dichroism (Figure 1). 
The circular dichroism spectrum for each of the proteins had a nadir at 218 nm indicating the 
secondary structure was predominantly β-sheet in agreement with the published structures for DENV 
EDIII (Figure 1, [7]). 
For EDIII biopanning with HX02, three different biopanning strategies were employed and varying 
levels of stringency applied in repeated attempts to enrich for EDIII binding clones (Table 1). Initially 
EDIII from DENV1 was coated onto an immunotube at a concentration of 50 μg/mL and subject to 
three rounds of biopanning using E. coli TG1 cells to amplify phage. Next, EDIII from DENV1 was 
coated into an immunoplate with a starting concentration of 20 μg/mL and E. coli XL-I blue cells were 
used to amplify phage in six rounds of biopanning. Finally, EDIII from DENV1 and 2 was biotinylated 
and immobilized on magnetic streptavidin resin for solution based panning. Such solution-based 
approaches avoid denaturation of epitopes that can occur when coating antigens in plastic [22]. Despite 
screening in excess of 1000 clones across these three different strategies by phage enzyme-linked 
immunosorbant assay (ELISA), no EDIII specific antibodies were identified from the HX02 naïve 
human library when the EDIII domain was used as bait. 
Table 1. Summary of phage display biopanning strategies against DENV envelope with 
the Naïve Human Fab Library (HX02). 
Procedure  Strategy 1  Strategy 2  Strategy 3  Strategy 4 
Antigen 
immobilisation 
DENV1 EDIII 
Immunotube 
DENV1 EDIII 
Immunoplate 
Biotinylated EDIII 
(DENV1 and DENV2) 
Streptavidin resin 
DENV1 whole virus 
Immunoplate 
Antigen 
concentration 
50 g/mL (Pan1) 
25 g/mL, (Pan2&3) 
10 g/mL (Pan1–4)
1 g/mL (Pan5&6)
100 nM (Pan1&2) 
50 nM (Pan3–6) 
20 g/mL (Pan1&2)
10 g/mL (Pan3&4)
Rounds of 
panning 
Three rounds  Six rounds  Six rounds  Four rounds 
E. coli strain  TG1  XL-1 Blue  TG1  XL-1 Blue 
Clone screening  190 (Pan3) 
95 (Pan4), 95 (Pan5), 
95 (Pan6) 
95 (Pan3), 285 (Pan5), 
190 (Pan6) 
384 (Pan4) 
DENV positive 
clones 
Nil Nil  Nil  188/384 
2.2. Biopanning the HX02 Library with DENV Virus Particles 
To determine the presence of anti-DENV envelope antibodies in the naïve library, DENV1 virus 
particles were purified from the supernatant of infected C6/36 cells using a sucrose gradient and used 
as antigen. Four rounds of panning against DENV1 virus coated onto an immunoplate at 20 μg/mL 
were performed with HX02 phage (Table 1). Success was evident by a primary screen of 384 clones Int. J. Mol. Sci. 2012, 13                 
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by phage ELISA with DENV1 that gave 188 positive hits. Diagnostic BstN1 digests enabled grouping 
of clones with similar DNA fingerprints and sequencing confirmed the identification of six unique 
clones. Sequence analysis with IMGT/V-QUEST showed that the VH sequences belong to the VH1, 
VH3 or VH4 gene families while the variable light VL sequences selected are derived from both kappa 
and lambda gene families (Vκ1, Vκ2, Vλ1, Vλ2) (Figure 2A). The heavy chain CDR3 sequences, which 
have a large influence over antibody binding specificity [23], are diverse in length and composition. 
Figure 2. Biopanning the HX02 naïve library with DENV1 whole virus particles and 
characterization of the anti-DENV Fabs identified. (A) Sequence analysis and variable 
gene usage of anti-DENV Fab. Shown are the complementary determining region 3 (CDR3) 
and variable gene family designations, assigned using IMGT/V Quest [24] (B) Phage 
ELISA of the six unique Fab-phage clones against DENV1 virus (small check), DENV2 
virus (large check), DENV1 EDIII (horizontal line) and BSA (vertical line);   
(C) An ELISA of purified Fab against DENV1 virus (closed symbols) and DENV2 virus 
(open symbols); (D) A Western blot of selected Fab with whole virus and Esol from DENV1. 
4G2 and 2H2 are control mouse mAbs, which bind E and prM proteins, respectively. 
 Int. J. Mol. Sci. 2012, 13                 
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To ascertain the specificity and DENV cross-reactivity of the six unique Fab phage clones a phage 
ELISA was performed against DENV virus particles from serotypes 1 and 2 and EDIII from DENV1. 
All of the six Fab-phage clones gave clear positive reactivity with the biopanning antigen, DENV1 virus, 
compared with the control BSA (Figure 2B). Fab-phage clones 2, 5, 6 and 9 also gave clear signals 
against DENV2 virus suggesting these clones are cross-reactive. None of the clones had reactivity with 
EDIII indicating the epitopes for these clones are not contained within domain III (aa295-395) of the 
viral envelope protein. 
2.3. Characterisation of the Unique Anti-DENV Antibodies 
The phagemids of the six unique clones were digested with SalI to remove the gene III sequence 
and enable expression of the soluble Fab in E. coli Top10 F′ cells. ELISA with the six purified Fabs 
confirmed binding to DENV virus as shown for Fab 2, 5 and 6 in Figure 2C. Fab 5 had the highest 
reactivity with DENV1 and DENV2 of the group of Fabs. As with the phage ELISA, none of the 
purified Fabs had reactivity with EDIII (data not shown). In the absence of any EDIII binders, DENV 
virions were resolved by SDS-PAGE and subjected to Western blot to identify the viral structural 
protein recognized by the Fabs. All of the Fab, and the 4G2 control that binds the fusion loop in EDII, 
detected a protein of approximately 65 kDa (Figure 2D), which corresponds to the viral envelope 
protein. None of the Fabs detected the 25 kDa protein that corresponds to precursor membrane (prM) 
protein seen with the 2H2 control. Intriguingly, four of the Fab (2, 5, 6 and 26) bound whole virus 
particles, but not the recombinantly expressed, soluble Ectodomain (Esol, aa1-400). The remaining 
Fab (9 and 25) detected Esol by Western blot, and since they are negative against EDIII (Figure 2A), it 
can be assumed their epitopes are contained within aa1-290 of Esol (EDI and EDII). 
As Fab 5 bound DENV with the highest avidity (Figure 2C), the ability of the antibody to neutralize 
DENV1 virus was examined. It was only weakly neutralising in the Fab format (30% neutralization at 
1.75 mg/mL) and as such this panel of human Fabs was not pursued further. 
2.4. Generation and Biopanning with the Chimeric Library 
To generate a phage library highly enriched for EDIII binding Fab, the mRNA from 10 hybridomas 
previously shown to bind DENV2 EDIII [20] were collected. The Vκ and VH encoding sequences 
from each hybridoma were separately amplified using published protocols [25], and then pooled in 
equal quantities to facilitate chain swapping during library generation and the generation of novel Fab 
in the enriched anti-EDIII hybridoma library. The Vκ and VH pools were subject to overlap PCR  
to generate Vκ/human Cκ and mouse VH/human CH cassettes, which were ligated into the pComb3X 
phagemid. The resulting chimeric library comprised approximately 2 × 10
6 independent transformants. 
Phage ELISAs with clones from the transformation plate showed 5/40 (12.5%) of clones were positive 
for DENV2 EDIII before biopanning. Over 90% of clones sequenced from the unselected library 
encoded functional Fab and there were several Fab with the same heavy chain and different light chain 
(and vice versa) indicating chain swapping had occurred during library generation. 
Three rounds of panning with DENV2 EDIII coated on an immunoplate were performed with the 
chimeric library. In a phage ELISA 44/96 (45.8%) of clones were positive for EDIII demonstrating 
selection had occurred during biopanning. Selected clones were subject to sequencing and it was found Int. J. Mol. Sci. 2012, 13                 
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that all positive clones had one of two Fab sequences, C9 or F1 (Figure 3A). These Fab-phage clones 
express the same heavy chain (VH1), and their light chain framework (Vκ1) and CDR3 are identical, 
but they differ in the CDR1 and CDR2 in their light chain. 
Figure 3. (A) Amino acid sequence alignment of mouse variable domains of chimeric 
mouse/human Fab clones C9 and F1. Shown are the framework regions (FR) and complementary 
determining regions (CDR) of the Vκ1 and VH1 using Kabat numbering [26]. Notable 
sequences differences are highlighted in grey and G91 and W96 in LCDR3 are marked (*); 
(B) Binding of C9 and F1 Fab and C9 IgG to DENV1-4 EDIII and DENV2 and 3 whole 
virus (D2WV, D3WV); (C) Elisa for C9 IgG (30 nmol/L) against DENV2 whole virus 
particles competed with increasing concentrations of mouse 9F12 and 3H5 IgG. C9 IgG 
binding was detected with an anti-human horseradish peroxidase (HRP) conjugate. 
 
2.5. Characterisation of Anti-EDIII Fab and IgG 
The phagemids for C9 and F1 were transformed into E. coli Top10 F′ cells for Fab expression and 
the specificity and DENV cross-reactivity of the Fabs were assessed by ELISA (Figure 3B). C9 had 
strong binding for EDIII from DENV2 and to a lesser extent with EDIII from DENV1 and DENV3. It 
had no reactivity with EDIII from DENV4. F1 also had strong binding with EDIII from DENV2, but 
the cross-reactivity with EDIII from DENV1 and 3 was reduced compared with C9. The reactivity 
with whole virus from DENV2 and DENV3 for both C9 and F1 was low in the Fab format. 
Given the superior cross-reactivity profile of C9, this Fab was cloned into the PIGG vector [27] for 
IgG expression in HEK293T cells. The C9 IgG had the same cross-reactivity profile as C9 Fab with 
the highest avidity seen with DENV2 EDIII, followed by EDIII from DENV1 and 3. On average, 
conversion of the monovalent Fab to bivalent IgG resulted in a 30 times stronger interaction with each 
EDIII antigen, which is comparable to published avidity gains [28]. Despite having reactivity with Int. J. Mol. Sci. 2012, 13                 
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EDIII from DENV3, the IgG did not detect whole virus particles from DENV3, but binding with 
DENV2 whole virus is clearly observed in the IgG format (Figure 3B). 
To ascertain the binding site for C9 IgG on EDIII, competition ELISAs were performed with two 
well-characterized EDIII specific mAb (Figure 1B); 3H5 for which the epitope has been shown to 
include aa383-386 in the FG loop [29], and 9F12 that binds the A-strand and G330 in the BC loop [20]. 
DENV2 virus was coated onto an immunoplate and incubated with increasing concentrations of mouse 
3H5 and 9F12. C9 IgG was added at a fixed concentration of 30 nmol/L and binding was detected with 
an anti-human IgG HRP conjugate. High concentrations of 9F12, but not 3H5, partially competed with 
C9 IgG binding (Figure 3C), indicating there is some overlap between the epitopes for 9F12 and C9. 
The reactivity of the C9 IgG with the DENV virion was further examined using immunofluorescence 
staining of DENV2 infected BHK 21 cells (Figure 4A). Both C9 IgG, and the control antibody 4G2, 
produced clear fluorescence intensity in the cytoplasm of DENV2 infected cells 24 h post infection 
(panel II and IV), with no evidence of cross reactivity with other cellular components in the uninfected 
cells (panel I and III). The neutralization of C9 IgG against DENV2 was examined using plaque 
reduction neutralization tests (PRNT). The purified IgG was moderately neutralizing. At a concentration 
of 1 μM (0.15 mg/mL) it significantly reduced the number of plaques formed by 25% (p < 0.001), 
compared with a 95% reduction observed with 4G2 (Figure 4B). The 50% neutralization point for C9 
IgG is 0.85 mg/mL, compared with 0.015 mg/mL for 4G2, the positive control (data not shown). 
Figure 4. (A) Immunofluorescence of uninfected BHK-21 cells (panel I and III) and cells 
infected with DENV2 (panel II and IV). Cells were incubated with C9 IgG (panel I and II) 
or 4G2 (3 nmol/L, panel III and IV) followed by goat anti-human or anti-mouse AF594 
(Invitrogen), and mounted with ProLong Gold containing DAPI; (B) Plaque reduction 
neutralization test performed with DENV2 in BHK21 cells. Virus was incubated with C9 
IgG or 4G2 (1 μM) prior to infection. Statistical significance (p < 0.001) is marked (*). 
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2.6. Saturation Mutagenesis of C9 Light Chain 
In an attempt to improve the affinity and neutralization of C9 a Fab-phage library was constructed 
to optimize the VL CDR3. This CDR was focused on as, although the VH and VL CDR3 are generally 
responsible for high affinity interactions with antigen, some studies have shown that mutations in  
the VH CDR3 almost always abolish binding [30]. Comparison of the C9 light chain sequence with F1 
(Figure 3A) also suggested that alterations within the VL CDR1 and CDR2 could reduce the cross 
reactivity propensity of the Fab. 
For VL CDR3 optimization, a segment of 7 amino acids, which covers the V-J joining region was 
randomized by NNK doping as previously published [25,27]. Randomisation of the G91 and W96 
within the CDR3 was avoided (Figure 3A) as glycine is critical for turns and tryptophan often has a 
critical structural role in CDRs [30,31]. Overlap PCR with the NNK doped primers yielded a library of 
4 × 10
5 independent transformants. Twelve test clones sequenced from the transformation plate had  
a unique VL CDR3 with the exception of the non-randomized glycine and tryptophan. The LCDR3 
Fab-phage library was selected by four rounds of biopanning against DENV2 EDIII immobilized in an 
immunoplate. A highly stringent off-rate selection was included in rounds 2–4. Phage were allowed to 
compete for binding to immobilized EDIII in the presence of high concentrations of EDIII for 24 h, as 
the rate of dissociation often distinguishes primary from affinity matured antibodies [32]. Approximately 
70% of clones were positive for EDIII in a phage ELISA following biopanning. However every positive 
clone sequenced had a LCDR3 identical to C9. Only clones that did not bind EDIII had unique VL 
CDR3 sequences suggesting that, at least amongst the 4 × 10
5 clones in the library, the residues in C9 
LCDR3 are optimal for antigen recognition. 
3. Discussion 
This study has used phage display as a central technique to identify and characterize anti-DENV 
antibodies, with the primary goal being the isolation of an EDIII specific antibody, since both human 
and mouse antibodies that target EDIII have been shown to be highly neutralizing [15,19]. Initial 
investigations with a naïve human library (HX02) and recombinant EDIII as antigen did not yield any 
anti-EDIII antibodies despite multiple panning strategies and exhaustive clone screening. This lack of 
EDIII specific clones is unlikely to be a reflection of library quality, but rather extremely low levels of 
anti-EDIII antibodies in the naïve human repertoire since DENV positive/EDIII negative Fab were 
identified when whole virus particles were used as antigen. Furthermore, we and others have successfully 
used the HX02 library to isolate antibodies specific for dengue non-structural proteins [33,34] and 
hemagglutinin of H5N1 influenza [35]. Previous phage display studies with the closely related WNV 
also support the hypothesis. When a naïve human scFv library was used for panning with purified WNV 
E protein, 11 antibodies with specificity for EDI and EDII were identified, but no antibodies with 
specificity for EDIII were isolated [36]. EDIII specific antibodies were identified in a subsequent study 
where immune libraries derived from three WNV infected patients were used for biopanning [37].  
But even then, the proportion of EDIII specific mAbs was low (4/51, 8%) compared with domain II 
(24/51, 47%). Int. J. Mol. Sci. 2012, 13                 
 
 
2627
The six Fabs identified by panning the HX02 library against DENV1 virus all bound the DENV 
envelope, but only two of them reacted with Esol (aa1-400). The Esol used in this study lacks the 
stem/transmembrane region (aa401-495) of the viral envelope protein and it is possible that some of 
the Esol negative Fab bind to these regions. Some may also bind E protein epitopes that are only 
available in the context of the native virion. Similar observations were made in two recent studies that 
examined the antibody response of humans exposed to primary DENV infections where over 90% of the 
mAbs generated bound DENV virus particles but not Esol [19,38]. The majority of mAbs identified in 
these studies were weakly neutralizing, and it was concluded that only a small fraction of DENV-specific 
antibodies in immune sera are responsible for neutralization. Our neutralization tests with Fab 5, which 
had the highest reactivity with DENV virus particles by ELISA, were not encouraging suggesting that a 
non-immune, human repertoire is not an ideal source of neutralizing antibodies for DENV. 
To increase the possibility of isolating neutralizing, EDIII specific mAbs by phage display, an 
immune library could be generated from DENV infected patients. However, the low percentage of 
EDIII positive clones in WNV immune libraries [37], and the DENV studies with immune sera that 
show EDIII mAbs are of low abundance in the human repertoire [19,38] suggest biopanning a human, 
DENV immune library would not be without challenges. As an alternative we decided to exploit the 
strong anti-DENV EDIII response exhibited by mice [12,13,15], and generated a chimeric mouse 
human Fab phage library in which the VL and VH were derived from a panel of previously generated 
anti-EDIII hybridomas [20], and the CL and CH were of human origin. Constructing a chimeric library 
ensures that the Fabs have a human constant region, which would be beneficial for latter therapeutic 
development. The two Fabs identified by biopanning against EDIII, C9 and F1, share the same heavy 
chain suggesting that of the 10 heavy chains included in the initial mRNA pool, this VH1 chain has 
superior EDIII binding. The Fabs had strong reactivity with DENV2 EDIII, but the cross-reactivity of F1 
towards EDIII from DENV1 and 3 was reduced compared with C9. The VL CDR1 and CDR2 in C9 and 
F1 differ in sequence, and though the Asn to Thr mutation in F1 LCDR1 is relatively conservative, the 
gain of positive charge in the F1 LCDR2 conferred by the Ser to Lys mutation may affect hydrogen 
bonding and antigen binding. Saturation mutagenesis of the LCDR3 in C9 indicated that any amino acid 
substitutions in this CDR abolish EDIII binding. This is consistent with an antigen recognition model in 
which the highly diverse CDR3 loops are the key determinants of specificity and modifications in the 
germ-line encoded CDR1 and CDR2 sequences have less impact [23]. 
Conversion of C9 to an IgG resulted in good avidity gains against DENV1-3 EDIII antigens and 
DENV2 whole virus, though the IgG had no reactivity with DENV3 despite binding DENV3 EDIII. 
The C9 epitope overlaps, in part, with that of 9F12 (A strand and BC loop), but a significant portion of 
the C9 epitope must be DENV2 specific since it has the highest reactivity to DENV2 EDIII. The lack 
of C9 binding with the DENV3 virion implies the residues that enable C9 to cross-react with 
DENV1-3 EDIII are not solvent accessible in the DENV3 virion. In effect this means that even with 
DENV2, not all of the C9 epitope can be engaged in the context of the virion. This probably explains 
why the IgG is only moderately neutralizing as epitope accessibility has been correlated with 
neutralization [39]. The moderate neutralization exhibited by C9 IgG is comparable to that of 9F12 
IgG [20], but is several orders of magnitude higher than recently discovered anti-EDIII mAbs with 
therapeutic potential [13,19]. Nevertheless, C9 is a well-characterized antibody and a useful research 
tool. Its isolation has provided an EDIII specific antibody that can be readily produced without the Int. J. Mol. Sci. 2012, 13                 
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concern of cell-line instability associated with hybridomas [21], and the human Fc enables antibody 
dependent enhancement studies to be conducted with human cell lines [18,19]. 
4. Materials and Methods 
4.1. Antigen Preparation 
EDIII antigens (aa295-395) from each of the four serotypes (DENV1 Hawaii, Genbank X76219; 
DENV2 TSV01, AY037116; DENV3 H87, M93130; DENV4 H241, AY947539) were refolded  
from inclusion bodies following expression in E. coli BL21 (DE3) cells as described [20] with minor 
modifications. Briefly, inclusion bodies were washed in 1 M urea and 2% Triton X 100, clarified by 
centrifugation, and solubilized in 20 mM Tris-HCl pH 8.5, 8 M urea, 150 mM NaCl, 10 mM imidazole 
and 10 mM β-ME. Proteins were loaded onto a Ni-NTA column (GE Healthcare) pre-equilibrated  
with the same buffer, eluted with an imidazole gradient and collected for refolding. Refolding was 
performed by dialysis in 200 mM Tris pH 8.5, 10 mM EDTA, 5 mM reduced glutathione, 0.5 mM 
oxidative glutathione and 100 mM arginine. A final SEC step with a Superdex 200 10/300 column (GE 
Healthcare) was conducted in 20 mM Tris pH 8.5 and 250 mM NaCl prior to storage. 
For whole virus particles, mosquito C6/36 cells were infected with DENV1-4 (serotypes as above) 
at an MOI of 0.1. The infected cell supernatant was harvested on day 5 post-infection and layered on top 
of a sucrose gradient ranging 11–55% in Phosphate Buffered Saline (PBS). Following centrifugation at  
4 °C, 75,000 g for 18 h, fractions containing DENV were pooled, concentrated and buffer exchanged into 
PBS using a centrifugal concentrator (MWCO 100,000 Da, Millipore). Infectious titer was determined by 
a standard plaque assay on BHK 21 cells. Virus particles were UV-inactivated prior to use in biopanning 
experiments, and quantified by Western blot with 4G2. 
The recombinant ectodomain of DENV1 (Esol, aa1-400) was a kind gift from Drs Petra Kukkaro 
and Shee Mei Lok (Duke-NUS Graduate Medical School, Singapore). The protein was expressed in 
Drosophila melanogaster S2 cells and purified as previously described [7]. 
4.2. HX02 Fab-Phage Library Biopanning 
Library screening was performed with a naïve human Fab phage display library HX02 (Humanyx 
Pte Ltd, Singapore) displayed in a modified pCES1 vector [40]. Panning was performed as described 
previously [33] but several different antigen immobilization strategies were utilized (Table 1). In  
all experiments the number of PBS-T (0.1% Tween-20) wash steps was increased, and antigen 
concentration decreased, during the biopanning cycles to increase stringency. Initially, EDIII from 
DENV1 was coated onto an immunotube (Nunc International) at a concentration of 50 μg/mL in PBS, 
pH 7.4. Phage (1 × 10
12) were added to the tube and allowed to bind for 1.5 h at room temperature. 
Non-specifically bound phage was removed with the number of wash steps shown in Table 1 and 
bound phage was eluted with 100 mM triethylamine. Eluted phage was used to infect E. coli TGI  
cells, cultures were rescued with M13K07 helper phage, and amplified phage was concentrated by 
polyethylene glycol-NaCl precipitation 
In the next panning experiment, EDIII from DENV1 was coated in four wells of an immunoplate 
(Nunc International) at a concentration of 10 μg/mL in 50 mM Na2CO3 pH 9.6. Phage were added to Int. J. Mol. Sci. 2012, 13                 
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the wells and allowed to bind for 2 h at room temperature prior to washing, glycine elution, and 
amplification in E. coli XL-1 Blue cells (Table 1). In the third EDIII panning experiment, antigen from 
DENV1 and DENV2 was biotinylated with a 20 fold molar excess of NHS PEG4 Biotin reagent (Pierce) 
on ice for 2 h according to the manufacturers instructions (Thermo Fisher Scientific). The reaction was 
stopped with 100 mM glycine and excess biotin was removed by size exclusion chromatography. Both 
DENV1 and DENV2 were immobilized on streptavidin magnetic beads (Invitrogen) at a concentration 
of 100 nM for biopanning. Finally, when whole virus particles (DENV1) were used as bait, virus was 
coated in four wells of an immunoplate at 20 μg/mL in PBS, pH 7.4 prior to incubation with phage. 
4.3. Construction and Biopanning of the Chimeric Fab-Phage Library 
Total mRNA was prepared from 10 hybridomas that had been previously generated by immunizing 
BALB/c mice with EDIII from DENV2 TSV01 (AY037116), as described [20]. RT-PCR amplification 
of mouse Vκ and VH was performed for each hybridoma using published primers and protocols [25]. 
The Vκ and VH PCR products were pooled and mouse Vκ/human Cκ and mouse VH/human CH 
segments were assembled in overlap PCR reactions using 100 ng of each product with published 
protocols and primers [25]. A final overlap PCR was performed to combine the light and heavy  
chain segments into a single 1.5 kB product for cloning into the pComb3X with SfiI as per  
published protocols [25]. 
The library was transformed into supercompetant E. coli XL-1 blue cells yielding approximately  
2 × 10
6 independent transformants. Selected clones from the library tranformation plate were sent for 
automated sequencing and screened for binding with DENV2 EDIII using a phage ELISA (method 
described below). The library was rescued with M13K07 helper phage and library phage (1 × 10
12) was 
incubated with EDIII from DENV2 (10 μg/mL) coated in four wells of an immunoplate for biopanning. 
Washing, elution and amplification steps were performed as described above for the HX02 library. 
4.4. Phage Clone Screening 
Following the third (or final) round of selection individual E. coli clones were rescued with M13K07 
and screened by ELISA for reactivity against EDIII or whole virus particles (coated in 50 mM Na2CO3 
pH 9.6 or PBS pH 7.4, respectively). An anti-M13 horseradish peroxidase (HRP) conjugate (GE 
Healthcare) was used for detection and clones with an absorbance value two times higher than 
background levels were considered positive. Clone uniqueness was assessed with a BstN1 restriction 
digest following PCR amplification of the Fab coding region of the phagemid as required. Clones with 
unique DNA fingerprints were subject to automated sequencing. 
4.5. Expression and Purification of Fab and IgG 
For HX02, phagemids from unique Fab-phage clones were digested with SalI to remove the gene 
III coding sequence and re-ligated with T4 DNA ligase as described [34]. The pComb3X chimeric 
clones have an amber stop for direct expression in non-suppressor strains of E. coli. HX02 or pComb3X 
plasmids were transformed into E. coli Top10 F′ cells (Invitrogen) for expression and periplasmic 
extraction. Cell pellets were resuspended in chilled lysis buffer (120 mM Tris pH 8.0, 0.3 mM EDTA Int. J. Mol. Sci. 2012, 13                 
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and 300 mM sucrose) and incubated on ice for 30 minutes for periplasmic extraction. Magnesium 
chloride (2.5 mM) was added to the clarified extract prior to immobilized metal affinity chromatography 
(IMAC) purification. Fabs were subject to a final purification step by SEC (S200 10/300 column)  
as required. 
For expression of the C9 IgG the previously described PIGG vector was used [27], in which the 
heavy and light chains are expressed by an engineered bidirectional CMV promoter. The light chain 
encoding sequences of C9 were amplified using primers C9-light-5′ (GAGGAGAAGCTTGTTGCTC 
TGGATCTCTGGTGCCTACGGGGAACTCGACGTTTTGATG) with C-kappa 3′ (AATTATCTAG 
AATTAACACTCTCCCCTGTTGAAGCTCTTTGTGACGGGCAAGCTCAGGCCCTG) and cloned 
with HindIII/XbaI-ligation into PIGG. The heavy chain encoding sequences of C9 were amplified  
with primers C9-heavy-5′ (GAGGAGGAGCTCACTCCGAGGTTCAGCTTCAGCAATCTGG) and 
Universal heavy reverse (CCTGGCCGGCCTGGCCACTAGTGACCGATGGGCCCTTGGTGGAGGC) 
and cloned with ApaI/SacI-ligation into PIGG. The resulting plasmid was transfected into human 
embryonic kidney (HEK293T) cells with lipofectamine 2000 (Invitrogen, Carlsbad, USA) for   
transient IgG expression and subsequent purification on a recombinant Protein G column as   
previously described [34]. 
4.6. Elisa and Western Blot with Fab and IgG 
For ELISA Maxisorb immunoplates were coated with 5 μg/mL EDIII in 50 mM Na2CO3 pH 9.6 or 
whole virus in PBS pH 7.4 and blocked with 5% skim milk in PBS-T. Blocked wells were incubated 
with purified Fab or IgG at room temperature for 1 h. Plates were washed with PBS-T and incubated 
with an anti-c-myc HRP conjugate (Roche) for detection of HX02 Fab or an anti-human HRP conjugate 
(MyBiosource) for detection of chimeric Fab and IgG. 
For Western blot, infected cell extract, purified virus or EDIII proteins were separated by SDS-PAGE 
(12% or 15%), transferred to PVDF membrane, and Western blotted with Fab (100 nMol/L) or murine 
mAb 4G2 or 2H2 as controls. Anti-human or anti-mouse HRP conjugated secondary antibodies were 
used for detection. All blots were imaged on an ImageQuant RT ECL using ImageQuant TL software 
(GE Healthcare). 
4.7. Affinity Maturation of C9 light Chain by Phage Display 
The light chain CDR3 (LCDR3) library was constructed by saturation mutagenesis of the C9 Vκ 
CDR3 using published protocols [25,27]. The two fragments required for LCDR3 library assembly 
based on the C9 sequence were obtained with the PCR primer pairs OMPSEQ and F3-back (5′ GCAG 
AAATAAACTCCCAGATC) and C9-CDR3-NNK (5′ GATCTGGGAGTTTATTTCTGCNNKNNK 
GGTNNKNNKNNKNNKTGGNNKTTCGGTGGAGGGACAAAG) and GBACK. N is A, C, G or T 
and K is G or T. The bases encoding glycine (GGT) and tryptophan (TGG) that are within the CDR3, 
but were kept constant in the LCDR3 library synthesis, are underlined. Following an overlap PCR  
with the flanking primers (OMPSEQ and GBACK) the resulting 1.5 kB fragment with a randomized 
LCDR3 was cut with SfiI and ligated into the appropriately digested pComb3X phagemid vector. The 
library was transformed into supercompetant E. coli XL-1 blue cells yielding approximately 4 × 10
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independent transformants. Twelve clones from the library transformation plate were subject to 
automated DNA sequencing and revealed different LCDR3 sequences. 
The LCDR3 library was panned against DENV2 EDIII as described for the chimeric Fab-phage 
library with the inclusion of an “off-rate” election step [27]. In the second through the fourth cycles of 
panning 20 µg of DENV2 EDIII in PBS pH 7.4 was added to the well after removal of unbound phage 
by 5–10 washing steps. The plate was then incubated for 24 h at room temperature (off-rate selection) 
prior to five additional washing steps and glycine elution. After the fourth cycle, Fab-phage clones 
were tested for binding to immobilized EDIII by phage ELISA as described above. 
4.8. DENV Immunostaining and Neutralization Assays 
BHK-21 cells grown on cover slips at a density of 2 × 10
5 were infected with DENV2 (GenBank 
accession EU081177.1) at an MOI of 0.3. Cells were fixed 24 h post-infection with 80% acetone at  
4 °C for 15 min, and washed three times with PBS. Cells were blocked with 2% BSA in PBS overnight 
at 4 °C followed by an overnight incubation with primary antibody (C9 or 4G2, 13 nmol/L) at 4 °C. 
Cells were washed three times with PBS and incubated with goat anti-human or anti-mouse AF594 
(Invitrogen, Carlsbad, USA) for 2 h at 4 °C. Labeled cells were washed three times with PBS, mounted 
with ProLong Gold containing DAPI (Invitrogen, Carlsbad, USA) and imaged using an inverted 
fluorescence microscope (Olympus IX71, Center Valley, USA) at 40× magnification. Image analysis 
was performed with ImageJ software [41]. 
Antibody neutralization was measured by a PRNT with BHK-21 cells as previously described [20]. 
Briefly, antibodies were pre-mixed with 50 pfu of DENV and incubated for 2 h at 4 °C prior to 
incubation with BHK-21 cells at 37 °C for 2 h. The mixture was replaced with RPMI 1640, 1% 
carboxymethylcellulose and antibody, and plates were incubated at 37 °C with 5% CO2 for 4–5 days. 
Plaques were manually counted following formaldehyde fixation. 
5. Conclusions  
The lack of EDIII specific Fab identified from a large naïve human library, together with a relative 
abundance of anti-DENV Fab in the same library, suggest EDIII antibodies are all but absent from  
the DENV-naïve human repertoire. Though previous phage display studies with WNV and B-cell 
immortalization from DENV infected donors suggest the EDIII response is amplified following 
infection, the levels of EDIII antibodies remain dramatically lower than those directed towards EDI 
and EDII [19,37]. This contrasts with studies in mice where DENV is non-pathogenic, unless animals 
are immune-compromised, and wild-type mice exhibit strong B-cell responses to EDIII [12,13,15]. It 
appears DENV, like other pathogenic viruses [42,43], has evolved its receptor-binding domain (EDIII) 
to have immunosilent properties in humans to facilitate cell entry. 
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